Enhancing stem cell survival in vivo for tissue repair

Biotechnology Advances

Volumn 31, Issue 5, 2013, Pages 736-743

  Hyun, Jeong S ^a   Tran, Misha C ^a   Wong, Victor W ^a,b   Chung, Michael T ^a   Lo, David D ^a,c   Montoro, Daniel T ^a   Wan, Derrick C ^a   Longaker, Michael T ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Gene therapy; Scaffolds; Stem cell niche; Tissue regeneration

Indexed keywords

CELL SURVIVAL; CLINICAL UTILITY; INFLAMMATORY MEDIATORS; PROGENITOR CELL; REGENERATIVE MEDICINE; STEM-CELL NICHES; SURROUNDING ENVIRONMENT; UP-REGULATION;

CELL DEATH; GENE THERAPY; MOLECULAR BIOLOGY; SCAFFOLDS; STEM CELLS; TISSUE REGENERATION;

SCAFFOLDS (BIOLOGY);

TISSUE SCAFFOLD;

APOPTOSIS; DISEASE TREATMENT; GENETIC ENGINEERING; TECHNOLOGICAL DEVELOPMENT; WOUNDING;

ANIMAL; APOPTOSIS; CELL SURVIVAL; CYTOLOGY; GENE THERAPY; HUMAN; METHODOLOGY; PHYSIOLOGY; REGENERATION; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING;

ANIMALS; APOPTOSIS; CELL SURVIVAL; GENETIC THERAPY; HUMANS; REGENERATION; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84879421136     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2012.11.003     Document Type: Review

References (66)

1. Aguado B.A., et al. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng 2012, 7(8):806-815.
2. An M.C., Zhang N., Scott G., Montoro D., Wittkop T., Mooney S., et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012, 11(2):253-263. [Aug 3].
3. Beck B., Driessens G., Goossens S., et al. A vascular niche and VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 2011, 478(7639):399-403. [Oct 19].
4. Cohen D.E., Melton D. Turning straw into gold: directing cell fate for regenerative medicine. Nat Rev Genet 2011, 12(4):243-252. [Apr].
5. Cooke M.J., et al. Design of biomaterials to enhance stem cell survival when transplanted into the damaged central nervous system. Soft Matter 2010, 6:4988-4998.
6. Das H., George J.C., Joseph M., et al. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model. PLoS One 2009, 4:e7325.
7. Devarajan E., Sahin A.A., Chen J.S., et al. Down-regulation of caspase-3 in breast cancer: a possible mechanism for chemoresistance. Oncogene 2002, 21(57):8843-8851. [Dec 12].
8. Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321(5893):1218-1221. [Aug 29].
9. Domen J., Weissman I. Hematopoietic stem cells need two signals to prevent apoptosis; Bcl-2 can provide one of these, Kifl/C-KIT signaling the other. J Exp Med 2000, 192(12):1707-1718. [December 18].
10. Ebert A.D., Yu J., Rose F.F., Mattis V.B., Lorson C.L., Thomson J.A., et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457(7227):277-280. [Jan 15].
11. Ferrara N., Gerber J.P., Lecouter J. The biology of VEGF and its receptors. Nat Med 2003, 9(6):669-676. [Jun].
12. Figueiredo C., et al. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion 2010, 50:1690-1701.
13. Fong G.H., Takeda K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 2008, 15(4):635-641. [Apr].
14. Fong C.Y., Gauthaman K., Bongso A. Teratomas from pluripotent stem cells: a clinical hurdle. J Cell Biochem 2010, 111(4):769-781. [Nov 1].
15. Gerber H.P., Dixit V., Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998, 273:13313-13316.
16. Green D.R., Ferguson T.A. The role of Fas ligand in immune privilege. Nat Rev 2011, 2:917-924.
17. Griffith T.S., et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 267:1445-1449.
18. Grinnemo K.H., et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells 2008, 26:1850-1857.
19. Grusby M.J., et al. Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci U S A 1993, 90:3913-3917.
20. Hanley J., Rastegarlari G., Nathwani A.C. An introduction to induced pluripotent stem cells. Br J Haematol 2010, 151(1):16-24. [Oct].
21. Hanna J., Wernig M., Markoulaki S., Sun C.W., Meissner A., Cassady J.P., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318(5858):1920-1923. [Dec 21].
22. Heng B.C., Vinoth K.J., Liu H., et al. Low temperature tolerance of human embryonic stem cells. Int J Med Sci 2006, 3(4):124-129. [Jul 23].
23. Imai Y., Adachi Y., Shi M., et al. Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation. Stem Cells Dev 2010, 19:461-468.
24. Itzhaki I., Maizels L., Huber I., Gepstein A., Arbel G., Caspi O., et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol 2012, 60(11):990-1000. [Sep 11].
25. Karbekian Z., et al. Immunological barriers to stem-cell based cardiac repair. Stem Cell Rev Rep 2011, 7:315-325.
26. Karoubi G., et al. Single-cell hydrogel encapsulation for enhanced survival of human marrow stromal cells. Biomaterials 2009, 30:5445-5455.
27. Kurtz J., et al. CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance. Blood 2009, 113:3475-3484.
28. Laflamme M., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007, 25:1015-1024.
29. Lee H.J., Kis K.S., Park I.H., et al. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis, and functional recovery in mouse stroke model. PLoS One 2007, 2(1):e156. [Jan 17].
30. Lee G., Papapetrou E.P., Kim H., Chambers S.M., Tomishima M.J., Fasano C.A., et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461(7262):402-406. [Sep 17].
31. Lee R.H., Pulin A.A., Se M.J., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in the lungs are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5(1):54-63. [Jul 2].
32. Li F., Huang Q., Chen J., et al. Apoptotic cells activate the "phoenix rising" pathway to promote wound healing and tissue regeneration. Sci Signal 2010, 23:3(110). [Feb].
33. Liu L.X., Lu H., Luo Y., et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor. Biochem Biophys Res Commun 2002, 291(4):908-914. [Mar 8].
34. Moretti A., Bellin M., Jung C.B., Thies T.M., Takashima Y., Bernshausen A., et al. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J 2010, 24(3):700-711. [Mar].
35. Park I.H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., et al. Disease-specific induced pluripotent stem cells. Cell 2008, 134(5):877-886. [Sep 5].
36. Pati S., Gerber M.H., Mene T.D., et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PLoS One 2011, 6(9):e25171.
37. Pearl J., et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 2011, 8:309-317.
38. Pierschbacher M.D., et al. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 1984, 309:30-33.
39. Pronk C.J., Veiby O.P., Bryder D., et al. Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptors. J Exp Med 2011, 208(8):1563-1570. [Aug 1].
40. Rios C.N., Skoracki R.J., Mathur A.B. GNAS1 and PHD2 short-interfering RNA support bone regeneration in vitro and in vivo in a sheep model. Clin Orthop Relat Res 2012, 470(9):2541-2553. [Sep].
41. Robertson N.J., et al. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc Natl Acad Sci U S A 2007, 104:20920-20925.
42. Rui J., Dadsetan M., Runge M.B., et al. Controlled release of vascular endothelial growth factor using poly-lactic-co-glycolic acid microspheres: in vitro characterization and application in polycaprolactone fumarate nerve conduits. Acta Biomater 2012, 8(2):511-518. [Feb].
43. Rustad K., et al. Enhancement of mesenchymal stem cell angiogenic capacity and stemness by a biomimetic hydrogel scaffold. Biomaterials 2012, 33:80-90.
44. Sareen D., Ebert A., Heins B.M., et al. Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy. PLoS One 2012, 7(6):e39113.
45. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978, 4:7-25.
46. Sharma A.K., Bury M.I., Fuller N.J., et al. Growth factor release from a chemically modified elastomeric poly(1,8-octanediol-co-citrate) thin film promotes angiogenesis in vivo. J Biomed Mater Res A 2012, 100(3):561-570. [Mar].
47. Singer A.J., Clark R.A. Cutaneous wound healing. N Engl J Med 1999, 341(10):738-746. [Sep 2].
48. Stabenfeldt S.E., et al. Thermoreversible laminin-functionalized hydrogel for enural tissue engineering. J Biomed Mater Res A 2006, 77:718-725.
49. Su J., et al. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials 2010, 31:308-314.
50. Swijnenburg R.J., et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005, 112:I166-I172.
51. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676. [Aug 25].
52. Takeda K., Cowan A., Fong G.H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007, 116(7):774-781. [Aug 14].
53. Tan J., Weil B.R., Abarbanell A.M., et al. Ablation of TNF-alpha receptors influences mesenchymal stem cell-mediated cardiac protection against ischemia. Shock 2010, 34(3):236-242. [Sep].
54. Toriumi H., et al. Treatment of Parkinson's disease model mice with allogeneic embryonic stem cells: necessity of immunosuppressive treatment for sustained improvement. Neurol Res 2009, 31:220-227.
55. Wang Y., Zheng C.G., Jiang Y., Zhang J., Chen J., Yao C., et al. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. Cell Res 2012, 22(4):637-648. [Apr].
56. Weber-Nordt R.M., Henschler R., Schott E., et al. Interleukin-10 increases Bcl-2 expression and survival in primary human CD34+ hematopoietic progenitor cells. Blood 1996, 88(7):2549-2558. [Oct 1].
57. Wei L., Cui L., Snider B.J., et al. Transplantation of embryonic stem cells overexpressing Bcl-2 promotes functional recovery after transient cerebral ischemia. Neurobiol Dis 2005, 19:183-193.
58. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., Soldner F., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008, 105(15):5856-5861. [Apr 15].
59. Willerth S.M., Ebert S. Combining stem cells and biomaterial scaffolds for constructing tissues and cell delivery. StemBook 2011, Harvard Stem Cell Institute.
60. Wong V.W., et al. Engineered pullulan-collagen composite dermal hydrogels improve early cutaneous wound healing. Tissue Eng Part A 2011, 17:631-644.
61. Xu D., Alipio Z., Fink L.M., Adcock D.M., Yang J., Ward D.C., et al. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009, 106(3):808-813. [Jan 20].
62. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920. [Dec 21].
63. Zarembinski T.I., et al. The use of a hydrogel matrix as a cellular delivery vehicle in future cell-based therapies: biological and non-biological considerations. Regenerative medicine and tissue engineering-cells and biomaterials 2011, InTech. D. Eberli (Ed.).
64. Zhang M., et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 2001, 33:907.
65. Zhao T., et al. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-216.
66. Zou D., Zhang Z., He J., et al. Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1α mediated BMSCs. Biomaterials 2012, 33(7):2097-2108. [Mar].